Table 6: Adjusted OR after multivariate analysis for predictors of treatment outcome of loss to follow-up.

Characteristics Loss to follow up Other treatment categories aOR(95% CI)p-value
N (%)N (%)

Residence
 (i) Other7(4.3)154(95.7)2.41(0.84-6.91)0.102
 (ii) Dar16(9.4)155(90.6)

Diabetes
 (i) Yes1(20.0)4(80.0)0.29(0.04-2.08)0.216
 (ii) No19(8.9)295(91.1)

Smoking
 (i) Yes6(7.7)72(92.3)0.74(0.32-1.77)0.509
 (ii) No5(4.6)104(95.4)

HIV status
 (i) Yes8(6.9)108(93.1)0.96(0.34-2.76)0.943
 (ii) No15(6.9)201(93.1)

Alcohol use
 (i) Yes9(9.5)86(90.5)1.61(0.72-3.56)0.244
 (ii) No5(5.3)89(94.7)

Isoniazid
 (i) Resistant9(7.4)121(92.6)1.22(0.32-4.68)0.768
 (ii) Susceptible1(9.1)10(90.9)

Rifampicin
 (i) Resistant14(6.9)188(93.1)0.93(0.25-3.44)0.909
 (ii) Susceptible0(0.0)5(100.0)

Streptomycin
 (i) Resistant7(8.8)73(91.2)0.14(0.02-1.14)0.066
 (ii) Susceptible1(2.9)33(97.1)

Ethambutol
 (i) Resistant4(5.5)69(94.5)4.65(0.88-24.56)0.070
 (ii) Susceptible4(10.8)33(89.2)